In some cases, doxorubicin increases the risk of breast cancer, depending on the dosage. If you have received 200 mg/m² or more of doxorubicin without breast radiation, it is advisable to start mammography for breast cancer screening at age 30 or 8 years after treatment, whichever comes last.